Bon Secours Acquires Surgery Partners for $5.7 Billion as Healthcare M&A Accelerates

The Quick Take

• Bon Secours Mercy Health will acquire Surgery Partners at a $5.7 billion enterprise value
• Private equity backer Bain Capital retains an equity stake in Surgery Partners post-acquisition
• Deal adds to a wave of healthcare services M&A driven by the outpatient care model shift and scale economics

Bon Secours Mercy Health's $5.7 billion acquisition of Surgery Partners marks a significant consolidation move in the outpatient surgery center sector. Surgery Partners operates ambulatory surgery centers and surgical facilities across the US, a segment that has benefited from the industry-wide shift from inpatient to lower-cost outpatient procedures accelerated by insurer reimbursement trends. Bain Capital's decision to retain an equity stake signals confidence in the combined entity's growth trajectory, a structure common in take-private-to-strategic transactions where the PE sponsor views the strategic buyer as capable of unlocking operational synergies while providing liquidity for their fund portfolio.

The $5.7 billion enterprise valuation sets a pricing benchmark for similar ambulatory surgery center platform transactions, likely influencing valuations at peer surgery network operators. Bon Secours expands its outpatient footprint, reducing dependence on higher-cost inpatient hospital operations — a strategic move aligned with value-based care incentives from major commercial insurers and the Centers for Medicare and Medicaid Services. Private equity funds holding ambulatory surgery center portfolios will treat this deal as evidence of strong strategic buyer appetite, potentially accelerating exit timelines and deal flow in the broader outpatient healthcare services sector.

Key metrics to monitor include the deal's regulatory review timeline under antitrust scrutiny given healthcare concentration implications of large hospital system acquisitions of surgery networks. Watch for competing bids or topping offers, which are common in healthcare M&A when strategic buyers perceive scarcity value in ambulatory platforms. The macro determinant is the reimbursement rate environment: CMS policy decisions on ASC procedure rates in the next fee schedule update will directly impact the acquired platform's revenue profile. Bain Capital's retained stake creates an ongoing alignment mechanism, meaning execution risk is partially shared, reducing the probability of post-close operational deterioration.

Synthesized from 1 source.